Assessing Whether Clover Health (CLOV) Looks Undervalued After Recent Share Price Moves

Assessing recent moves in Clover Health Investments (CLOV)

Clover Health Investments (CLOV) has drawn investor attention after recent share price moves, with the stock last closing at US$2.19 and showing mixed returns across the past week, month, and past 3 months.

See our latest analysis for Clover Health Investments.

For context, the recent 13.47% 7 day share price return and 16.49% 30 day share price return come after a weaker 90 day share price return of 13.78% and a 1 year total shareholder return of 39.17%. This suggests short term momentum has picked up even as longer term performance has been challenging.

If you are comparing Clover Health with other healthcare names benefiting from AI and data driven tools, it can be useful to scan a wider set of ideas using the 35 healthcare AI stocks

With Clover Health reporting US$1.9b in revenue, a net loss of US$85.5m, and trading at US$2.19, are investors looking at a stock with upside still on the table, or is the market already pricing in future growth?

Most Popular Narrative: 22.2% Undervalued

At a last close of $2.19 versus a narrative fair value of $2.82, the widely followed thesis sees Clover Health as pricing in a meaningful discount while still hinging on execution and margins catching up.

The company’s differentiated technology driven care model, particularly the Clover Assistant platform, positions it to benefit from the healthcare industry’s accelerated shift toward technology adoption and data driven, value based care, supporting lower medical costs and higher medical margins, with positive implications for both revenue growth and net margins.

Read the complete narrative.

Curious what kind of revenue build, margin lift, and future earnings multiple are baked into that fair value, and how a modest discount rate ties it all together.

Result: Fair Value of $2.82 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, the story could shift quickly if medical costs continue to pressure benefit expense ratios or if Medicare Advantage reimbursement or 4-star bonus rules become less favorable.

Find out about the key risks to this Clover Health Investments narrative.

Next Steps

Mixed signals across price moves and fundamentals can split opinions, so act while the information is fresh and weigh both sides by checking the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you might miss other opportunities that fit your style, so widen your search now and let the data work for you.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com